Use of a ganoderma lucidum extract and a hericium erinaceus extract for the treatment of the side effects of radiotherapy and / or chemotherapy on the skin

A topical composition of Ganoderma lucidum and Hericium erinaceus extracts addresses the inflammatory side effects of cancer treatments by reducing cytokine expression, offering improved anti-inflammatory effects for skin protection.

WO2024240975A1PCT designated stage expired Publication Date: 2024-11-28HIFAS DA TERRA SL
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/ES2024/070290
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-14
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for cancer, such as radiotherapy and chemotherapy, often cause adverse skin reactions including inflammation, dermatitis, skin fragility, and dry skin, due to the induction of cytokines like IL-1, IL-6, and IL-8, which existing skin care products have not effectively addressed.

Method used

A topical composition combining extracts from Ganoderma lucidum and Hericium erinaceus, rich in bioactive compounds like p-glucans, ergosterol, and ganoderic acid, is administered topically to reduce inflammation and mitigate these side effects by directly targeting the skin, offering improved anti-inflammatory effects compared to individual extracts.

Benefits of technology

The combination of Ganoderma lucidum and Hericium erinaceus extracts significantly reduces the mRNA expression of pro-inflammatory cytokines IL-1, IL-6, and IL-8, providing enhanced anti-inflammatory benefits for treating and preventing side effects associated with radiotherapy and chemotherapy on the skin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000026_0001
    Figure IMGF000026_0001
Patent Text Reader

Abstract

The present invention relates to a topical composition comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus. Furthermore, the present invention relates to a combination of an extract obtained Ganoderma lucidum and an extract obtained from Hericium erinaceus for use in the treatment and / or prevention of the side effects of radiotherapy and / or chemotherapy on the skin of a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] USE OF A GANODERMA LUCIDUM EXTRACT AND A HERICIUM ERINACEUS EXTRACT FOR THE TREATMENT OF THE SIDE EFFECTS OF RADIOTHERAPY AND / OR CHEMOTHERAPY ON THE SKIN

[0003] The present invention is in the field of biomedicine, referring to a topical composition comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus, furthermore the present invention relates to a combination of an extract of Ganoderma lucidum and an extract obtained from Hericium erinaceus for use in the treatment and / or prevention of side effects of radiotherapy and / or chemotherapy on the skin of a subject.

[0004] BACKGROUND OF THE INVENTION

[0005] Cancer is one of the leading causes of morbidity and mortality in developed countries. New therapies and combinations have led to increased survival. However, adverse events associated with antineoplastic therapies are numerous.

[0006] The most common methods for treating cancer include radiation therapy and chemotherapy. Radiation therapy and chemotherapy can damage the skin, causing, for example, fibrosis, inflammation, dermatitis, skin fragility, skin fold erosions, nail loss, or dry skin.

[0007] Therefore, there is a need to provide compositions capable of preventing, curing, and / or alleviating the side effects of radiotherapy and / or chemotherapy on the skin. Exposure of the skin to ionizing radiation results in a cutaneous radiation reaction. Immediately after irradiation, cytokine production by skin cells initiates and continues as a cascade throughout all stages of cutaneous radiation syndrome. Cytokines are important signaling molecules that mediate communicative interactions both locally between different cell types within dermal tissues and remotely between organs. Scientific studies indicate that the main cytokines in the response of skin cells to ionizing radiation include IL-1, IL-6, and the chemokines IL-8.

[0008] The state of the art describes the use of extracts from fungi for the treatment and care of skin.

[0009] Document CN1 14344360A describes a preparation for the repair of minor skin injuries containing Ganoderma lucidum extract.

[0010] Mingyi, Y., et al., 2019 Trends in Food Science & Technology, 92, 94-110 refers to the use of fungal polysaccharides such as nutraceuticals, pharmaceuticals and cosmetics highlighting their activities as immunomodulators, antitumor and anti-inflammatories.

[0011] Taofiq, O., et al, 2016, Industrial Crops and Products, 90, 38-48, refers to the use of fungal ingredients to combat skin aging, hyperpigmentation and inflammation, being used as cosmeceuticals or nutricosmetics, due to their anti-tyrosinase, anti-hyaluronidase, anti-elastase and anti-collagenase activities.

[0012] Xu, H., International Journal of Biological Macromolecules, 47(1 ), 33-36 reports the effects of a polysaccharide extract of H. ehnaceus on improving skin antioxidant enzymes, MMP-1 and TIMP-1 activities, and collagen concentrations.

[0013] Document CN105816394 A describes a cream containing Hehcium ehnaceus extract. It can repair skin lesions and prevent radiation to protect the skin from injury. The anti-radiation effect is effective against electromagnetic radiation, ultraviolet rays, and microwave radiation.

[0014] Document KR20190027178A describes a cosmetic composition based on Centipeda minima extract, fermented with strains that include Hehcium ehnaceum, Pleurotus ferulae, Sparassis crispa, Ganoderma lucidum, Flammulina velutipes, Phellinus linteus and / or Grifóla frondosa.

[0015] Document CN108042588A discloses a nutraceutical composition comprising American ginseng root, Ganoderma lucidum and Hehcium ehnaceum, which improves immunity and can be applied after chemotherapy and radiotherapy.

[0016] Radiotherapy and chemotherapy can damage the skin. Therefore, there is a need to provide new compositions capable of preventing, treating, curing, and / or alleviating the side effects of radiotherapy and / or chemotherapy in an effective and improved manner, particularly those side effects affecting the skin.

[0017] DESCRIPTION OF THE INVENTION

[0018] The present inventors have developed a combination of fungal extracts for use in the treatment and / or prevention of the side effects of radiotherapy and / or chemotherapy on the skin of a subject.

[0019] The present inventors have obtained a greater in vitro anti-inflammatory activity in fibroblast cell lines by combining the carpophore extract of Hericium erinaceus, and the carpophore extract of Ganoderma lucidum, compared to these extracts individually (see Table 1 of the examples). Thus, based on the results obtained, the inventors have demonstrated an improved anti-inflammatory effect of the combination of the extracts of Hericium erinaceus, and Ganoderma lucidum, being of interest the use of said combination for the treatment and / or prevention of inflammatory conditions such as the side effects of radiotherapy and / or chemotherapy in the skin of a subject.

[0020] Preparations containing an extract obtained from the carpophore of Ganoderma lucidum or an extract obtained from the carpophore of Hericium erinaceus are known in the art. However, an extract obtained from Ganoderma lucidum in combination with an extract obtained from Hericium erinaceus has not previously been used for the prevention and / or treatment of the side effects of radiotherapy and / or chemotherapy on the skin. Furthermore, the present strategy for combating the side effects of radiotherapy and / or chemotherapy on the skin provides several advantages. By administering an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus directly to the site of action, a local improvement in immunity is achieved.Side effects can be minimized because by combining the extracts and administering them topically, the therapeutically effective dose can be more easily adjusted to achieve the desired effect, while also achieving an optimal dose-response.

[0021] Therefore, in a first aspect, the present invention relates to a topical composition, hereinafter “the composition of the invention”, comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus.

[0022] In the present invention, the term "topical composition" refers to a composition suitable for application to external tissues of a subject, such as the skin, scalp, eyelashes, eyebrows, nails, mucous membranes, and hair, preferably the skin. Thus, as understood by those skilled in the art, the composition of the invention is formulated for topical administration.

[0023] Ganoderma lucidum is a basidiomycete of the Ganodermataceae family and contains a large number of bioactive compounds, especially polysaccharides p-glucans, which are responsible for the antitumor, immunomodulatory, and antioxidant activities of this species.

[0024] The term “extract obtained from Ganoderma lucidum” refers to one or more compounds, substances, samples, concentrates, or isolated products obtained, derived, or extracted from the fungus Ganoderma lucidum. This includes complete extracts of Ganoderma lucidum, but also pure or semi-pure preparations of the biologically active compounds obtained from Ganoderma lucidum, preferably obtained from the Ganoderma lucidum carpophore, as well as from the carpophore powder. The Ganoderma lucidum extract can be obtained through physical and / or chemical extraction methods. The Ganoderma lucidum extract preferably also includes combinations of other known components and / or active compounds that combine to substantially mimic the composition and / or activity of a naturally occurring Ganoderma lucidum extract.In the present invention, the terms “extract obtained from Ganoderma lucidum” and “extract of Ganoderma lucidum” may be used interchangeably.

[0025] In a preferred embodiment, the Ganoderma lucidum extract comprises p-glucans, ergosterol and ganodenic acid.

[0026] In a more preferred embodiment, the G. lucidum extract comprises:

[0027] Between 524 mg / g and 641 mg / g of p-glucans;

[0028] Between 376 pg / g and 460 pg / g of ergosterol; and Between 4.30 pg / g and 5.30 pg / g of ganoderic acid.

[0029] In a more preferred embodiment, the G. lucidum extract comprises:

[0030] 583 mg / g of p-glucans;

[0031] 418 pg / g of ergosterol; and

[0032] - 4.81 pg / g of ganoderic acid.

[0033] The quantification of p-glucans, ergosterol, and ganoderic acid can be performed following standardized methodologies. p-glucans were quantified using the p-glucan Enzyme Kit (Megazyme, Neogen). Ergosterol was quantified by high-performance liquid chromatography coupled to mass spectrometry (HPLC-MS) following the methodology described by Montgomery et al. Soil Biology and Biochemistry. 2020; 32: 1207–1217, and ganoderic acid was quantified by HPLC-MS following the methodology described by Qui et al. Front Farmacol. 2012; 3: 85.

[0034] Hericium erinaceus is a basidiomycete of the Hericiaceae family, considered a natural prebiotic that helps restore the microbiota and contains a large number of bioactive compounds, especially p-glucan polysaccharides, which are responsible for the anticancer, immunomodulatory, antioxidant, neurostimulatory and neuroprotective activities of this species.

[0035] The term “extract obtained from Hericium erinaceus” refers to one or more compounds, substances, samples, concentrates, or isolated products obtained, derived, or extracted from the fungus Hericium erinaceus. This includes complete extracts of H. erinaceus, but also pure or semi-pure preparations of the biologically active compounds obtained from H. erinaceus, preferably obtained from the carpophore of H. erinaceus, as well as from the carpophore powder. The Hericium erinaceus extract can be obtained through physical and / or chemical extraction processes. The Hericium erinaceus extract preferably also includes combinations of other known components and / or active compounds that combine to substantially mimic the composition and / or activity of a naturally occurring H. erinaceus extract.In the present invention, the terms “extract obtained from Hericium erinaceus” and “extract of Hericium erinaceus” may be used interchangeably. In a preferred embodiment, the H. erinaceus extract comprises p-glucans, Y-aminobutyric acid, ergosterol and hericenone c.

[0036] In a more preferred embodiment, the H. erinaceus extract comprises:

[0037] Between 220 mg / g and 268 mg / g of p-glucans;

[0038] Between 46 pg / g and 56.32 pg / g of y-aminobutyric acid;

[0039] Between 313.39 pg / g and 382.80 pg / g of ergosterol; and

[0040] Between 0.18 pg / g and 0.22 pg / g of hericenone c.

[0041] In a more preferred embodiment, the H. erinaceus extract comprises:

[0042] 244 mg / g of p-glucans;

[0043] 51.2 pg / g of y-aminobutyric acid;

[0044] 348.21 pg / g of ergosterol; and

[0045] 0.2 pg / g hericenone c.

[0046] The quantification of p-glucans, y-aminobutyric acid, ergosterol, and hericenone c can be performed following standardized methodologies. p-glucans are quantified using the p-glucan Enzyme Kit (Megazyme). y-Aminobutyric acid is quantified by HPLC following the methodology described by Gong et al. J. Inst. Brew.2017; 123: 417-422; ergosterol is quantified by HPLC-MS following the methodology described by Montgomery et al. Soil Biology and Biochemistry. 2020; 32: 1207-1217, and hericenone c is quantified by HPLC following the methodology described by Lee et al. Journal of Ethnopharmacology. 2016; 184: 219-225.

[0047] In the present invention, the extract obtained from Ganoderma lucidum and the extract obtained from Hericium erinaceus are referred to as “the extracts of the invention”.

[0048] In a preferred embodiment of the composition of the invention, the extracts obtained from Ganoderma lucidum and Hericium erinaceus are obtained from the carpophore or mycelium of said fungi, preferably from the carpophore. Thus, in a preferred embodiment, the composition of the invention comprises an extract obtained from the carpophore of Ganoderma lucidum and an extract obtained from the carpophore of Hericium erinaceus. Therefore, in preferred embodiments, the concentration of p-glucans, ergosterol and ganoderic acid in the Ganoderma lucidum extract; and the concentration of p-glucans, y-aminobutyric acid, ergosterol and hericenone c in the Hericium erinaceus extract, described in previous embodiments, correspond to the concentrations of said compounds in extracts obtained from the carpophore of Ganoderma lucidum and the carpophore of Hericium erinaceus, respectively.

[0049] The term “carpophore” refers to the reproductive part of the fungus, also called the fruiting body, sporocarp, or mushroom.

[0050] The term “mycelium” refers to the set of hyphae that form the vegetative part of a fungus.

[0051] In another preferred embodiment, the composition of the invention comprises the extract of H. erinaceus in a concentration between 0.005% and 25%, in % m / m, and the extract of G. lucidum in a concentration between 0.005% and 25%, in % m / m, depending on the form in which said composition is presented, for example, depending on whether the composition is in gel, cream or ointment form. The % refers to the % m / m of each of the extracts with respect to the total composition.

[0052] In another even more preferred embodiment of the invention, the composition of the invention comprises the extract of H. erinaceus in a concentration between 0.25% m / m and 3% m / m, preferably in a concentration of 0.5% m / m, 1% m / m, 1.5% m / m, 2% m / m or 2.5% m / m, more preferably 0.5% m / m, and the extract of G. lucidum in a concentration between 0.25% m / m and 3% m / m, preferably in a concentration of 0.5% m / m, where the % refer to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

[0053] The term “%m / m” refers to the mass percentage of the extract, i.e. a measure of concentration indicating the mass of solute (e.g. H. erinaceus extract / G. lucidum extract) per 100 mass units of the composition.

[0054] Examples of methods for obtaining the extracts of the invention include, but are not limited to, pressing, maceration, stirred maceration, ultrasonic extraction, percolation or repercolation, steam distillation, hydrodistillation, decantation, filtration, evaporation, and / or chromatography. Preferably, the extraction method of the invention is percolation.

[0055] In a particular embodiment, the Ganoderma lucidum extract, particularly Ganoderma lucidum carpophore extract, or the Hericium erinaceus extract, particularly Hericium erinaceus carpophore extract, is obtained by a method, hereinafter “method of obtaining the invention”, comprising the following steps:

[0056] (i) mixing the whole carpophore or portions of carpophore preferably smaller than 5 cm, with an aqueous solution and / or alcohol, preferably in a solid:liquid ratio of 1:5 to 1:40;

[0057] (i) subjecting the heterogeneous mixture obtained in (i) to a temperature of between 20 e C and 70 e C for between 30 and 60 minutes, obtaining an infusion of the mixture obtained in (i); and

[0058] (iii) percolate or filter the infusion obtained in (iii), obtaining the carpophore extract in the liquid fraction or solution.

[0059] The extracts of the invention may be obtained from the whole carpophore or cut into small pieces or portions of a size less than 5 centimeters (cm), preferably less than 4 cm, more preferably less than 3 cm or less than 2 cm. In another particular embodiment of the method of obtaining the invention, the carpophore extract is obtained from carpophore portions of a size less than 1 cm.

[0060] In another more particular embodiment of the method of obtaining the invention, the carpophore extract is obtained by mixing the entire carpophore or the portions of the carpophore with a solvent, preferably where the solvent is selected from the list consisting of: an aqueous solution (more preferably water), an alcohol (more preferably ethanol, methanol, butanol, propanol-2 or pentanol), propane, butane, ethyl acetate, carbon dioxide, acetone, nitrous oxide or a mixture between them.

[0061] In another more particular embodiment of the method of obtaining the invention, the carpophore extract is obtained by mixing the entire carpophore or portions of the carpophore with an aqueous solution and alcohol, preferably water and / or alcohol.

[0062] In another even more particular embodiment of the method of obtaining the invention, the carpophore extract is obtained by mixing the entire carpophore or portions of the carpophore with water and / or ethanol, more preferably with a mixture of water and ethanol.

[0063] When a mixture of ethanol and water is used, preferably the ethanol is present in a proportion of between 10% by volume and 60% by volume (where the water would be present in a proportion between 90% and 40% by volume, respectively), more preferably between 20% and 60% by volume (where the water would be present in a proportion between 80% and 40% by volume, respectively), even more preferably between 40% and 60% by volume (where the water would be present in a proportion between 60% and 40% by volume, respectively).

[0064] In another more particular embodiment of the method of obtaining the invention, the carpophore extract is obtained by mixing the entire carpophore or the portions of the carpophore with water and ethanol in a water:ethanol ratio of 50% and 50% by volume, that is, in a water:ethanol ratio of 1:1.

[0065] In particular, for obtaining the carpophore extract, the proportion of whole carpophore or portions of the carpophore (solid) in the solvent (liquid), that is, the solid:liquid ratio, is from 1:5 to 1:40. In another particular embodiment, the proportion of whole carpophore or portions of carpophore (solid) in the solvent (liquid) is from 1:10 to 1:30, preferably 1:20.

[0066] The time required for extraction is usually adjusted to the initial fungal material, the extraction method, the extraction temperature, the ratio of solvent to fungal material, and the like.

[0067] Once the mixture of the entire carpophore or portions of the carpophore and the solvent is obtained, said mixture is subjected to a temperature between 20 and 70 e C for between 30 and 60 minutes (step (i)), obtaining an infusion of the mixture obtained.

[0068] In another more particular embodiment of the method of obtaining the invention, the mixture of the entire carpophore or the portions of the carpophore and the solvent is subjected to a temperature between 30 and 60 e C, preferably between 35 and 55 e C, for between 35 and 55 minutes, preferably between 40 and 50 minutes.

[0069] In another more particular embodiment of the method for obtaining the invention, the mixture of the entire carpophore or the portions of the carpophore and the solvent is subjected to a temperature of 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 or 54 e C for 41, 42, 43, 44, 45, 46, 47, 48 or 49 minutes.

[0070] In another even more preferred embodiment of the method of obtaining the invention, the mixture of the entire carpophore or the portions of the carpophore and the solvent is subjected to a temperature of 50 e C for 45 minutes.

[0071] Optionally, the extraction step can be repeated on the same solid under the same conditions described above, that is, optionally step (i) can be repeated at least once.

[0072] After extraction (step 1i), the mixture of solvent and extracted compounds that is formed after the solvent comes into contact with the fungal material is separated by solid-liquid filtration of the fungal material by methods such as percolation, obtaining in the liquid fraction the carpophore extract of the invention.

[0073] The term "percolation" refers to the action of a liquid penetrating, passing through, or moving through the pores of a body or environment; that is, the slow passage of fluids through porous materials. State-of-the-art synonyms for this term are filtration and leaching.

[0074] The bioactive compounds present in the extract, primarily phenolic compounds, typically have a limited shelf life due to oxidation. Therefore, additional drying of the extract (in the liquid fraction) can optionally be applied to extend its shelf life. One method that can be used for drying bioactive extracts is spray drying.

[0075] Thus, in another more preferred embodiment of the method of obtaining the invention, the method for obtaining the carpophore extract also comprises a step (iv) of spray drying the solution obtained in (iii) at a temperature between 135 e C to 195 e C. In another even more particular embodiment, the temperature of step (iv) is between 145 e C and 185 e C, preferably between 165 e C and 175 e C.

[0076] During spray drying, an encapsulating agent may be added, for example, maltodextrin.

[0077] Thus, in another more preferred embodiment, the method for obtaining the invention also comprises a step (v) of adding an encapsulating agent, preferably the encapsulating agent is in a proportion of between 1% m / m and 50% m / m (where the extracts would be in a proportion of between 99% m / m and 50% m / m, respectively), more preferably between 20% m / m and 40% m / m (where the extracts would be in a proportion of between 80% and 60% m / m, respectively), even more preferably between 25% m / m and 35% m / m (where the extracts would be in a proportion of between 75% m / m and 65% m / m, respectively).

[0078] In another more particular embodiment of the method of the invention, the proportion of the combination of extracts:encapsulating agent is 71.4% m / m and 28.57% m / m, that is, in a proportion of extracts:encapsulating agent of 4:14.

[0079] The term “encapsulating agent” refers to a substance and / or substances that prevent caking, caking, and stickiness of the ingredient undergoing spray drying, increasing its stability and improving its bioavailability. Examples of encapsulating agents include, but are not limited to, maltodextrin, starch and derivatives, corn syrups, sucrose, cyclodextrins, carboxymethylcellulose, methylcellulose, ethylcellulose, nitrocellulose, acetylcellulose, gum arabic, sodium alginate, carrageenan, mono- and diglycerides, whey, zein, gluten, and / or casein.

[0080] In another more preferred embodiment, the method for obtaining the extract of the invention further comprises a step (v) of adding an encapsulating agent, where the encapsulating agent is maltodextrin.

[0081] In a preferred embodiment, the composition of the invention is in liquid or semi-solid form, preferably in the form of a gel, cream or ointment.

[0082] The composition of the invention may be formulated (i) for pharmaceutical administration, i.e., alone or as part of pharmaceutical products administered to a subject, or (ii) for administration as a cosmetic to a subject, i.e., alone or as part of cosmetic products. Thus, in a particular embodiment, the composition of the invention is a pharmaceutical composition or a cosmetic composition. Hereinafter, respectively, "pharmaceutical composition of the invention" and "cosmetic composition of the invention".

[0083] The term "pharmaceutical composition" refers to a set, mixture, or combination of components or substances comprising the extracts of the invention in any concentration, and which improves the subject's health status or reduces the risk of disease. Said pharmaceutical composition may be a medicament. However, the term "pharmaceutical composition" also encompasses medical devices, provided that the "medical device" is intended for use in subjects, preferably humans, separately or in combination with other products, for any of the following specific medical purposes: prevention, treatment, or alleviation of a disease or treatment, alleviation, or compensation of an injury or disability, and its primary mechanism of action is not pharmacological, metabolic, or immunological.

[0084] In the present invention, the term "cosmetic composition" refers to a set, mixture, combination of components or substances comprising the extracts of the invention in any concentration intended to be placed in contact with the different external parts of the body of a subject (epidermis, hair system, nails, lips and external genital organs) with the exclusive or main purpose of cleaning them, perfuming them, modifying their appearance and / or correcting body odors and / or protecting them or keeping them in good condition.

[0085] In another preferred embodiment, the composition of the invention further comprises a vehicle and / or pharmaceutically or cosmetically acceptable excipients.

[0086] Thus, in another preferred embodiment, the pharmaceutically or cosmetically acceptable carrier and / or excipient of the composition of the invention is water, chitosan, hydroxypropyl methylcellulose, lactic acid, sodium hyaluronate, blueberry flavor, citric acid, sorbic acid, sodium benzoate, organic rice extract, rice fiber, rice protein, silicon dioxide, calcium carbonate, dicalcium phosphate, sorbitol, sucralose, xylitol and / or combinations thereof. In another more preferred embodiment, the pharmaceutically or cosmetically acceptable carrier and / or excipient of the composition of the invention is lactic acid, sodium hyaluronate, blueberry flavor, citric acid, sorbic acid, sodium benzoate, chitosan, water and / or combinations thereof.

[0087] As understood by those skilled in the art, the composition of the invention may comprise at least one bioactive component (active substance, active ingredient or therapeutic agent), such as, for example, prebiotics, probiotics, vitamins, minerals, plant or fungal products and / or drugs.

[0088] As researchers have shown, the combination comprising an extract of Hericium erinaceus, preferably an extract obtained from the carpophore of Hericium erinaceus, and an extract of Ganoderma lucidum, preferably an extract obtained from the carpophore of Ganoderma lucidum, hereinafter “combination of the invention”, has therapeutic properties, so that in another aspect, the present invention relates to the combination of the invention for use as a medicament where said medicament is administered topically, the “first medical use” of the invention.

[0089] The term “drug” refers to any substance or combination of substances that is presented as having properties for the treatment or prevention of diseases in a subject, or that can be used in a subject or administered to a subject for the purpose of restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or of establishing a medical diagnosis.

[0090] In a preferred embodiment of the first medical use of the invention, the extracts of Hericium erinaceus and Ganoderma lucidum are part of the topical composition of the invention.

[0091] In the present invention, the term "subject" refers to a human or any eukaryotic, heterotrophic, multicellular organism that is not a human, such as a non-human animal. Examples of non-human animals include, but are not limited to, non-human mammals such as non-human primates, horses, sheep, goats, pigs, dogs, cows, or cats.

[0092] The present inventors have surprisingly found that the combination comprising an extract obtained from Hericium erinaceus, and an extract obtained from Ganoderma lucidum exhibits anti-inflammatory effects which are beneficial for the treatment and / or prevention of side effects associated with radiotherapy and / or chemotherapy.

[0093] Specifically, the inventors found that administration of Ganoderma lucidum leaf extract combined with Hericium erinaceus leaf extract significantly reduced the mRNA expression of the proinflammatory cytokines IL-1, IL-6, and IL-8, especially IL-8, compared to administration of the fungal extracts alone. Thus, the inventors have demonstrated an improved anti-inflammatory effect of the combination of Ganoderma lucidum and Hericium erinaceus extracts compared to said extracts alone.

[0094] Thus, in another aspect, the present invention relates to the use of an extract obtained from Ganoderma lucidum, preferably an extract obtained from the carpophore of Ganoderma lucidum, and an extract obtained from Hericium erinaceus, preferably an extract obtained from the carpophore of Hericium erinaceus, for the preparation of a medicament for the treatment and / or prevention of side effects associated with radiotherapy and / or chemotherapy in a subject, preferably the side effects associated with radiotherapy and / or chemotherapy manifest themselves on the skin of the subject.

[0095] In another aspect, the present invention relates to the combination of the invention, that is, a combination comprising an extract obtained from Ganoderma lucidum, and an extract obtained from Hericium erinaceus, for use in the treatment and / or prevention of the side effects of radiotherapy and / or chemotherapy on the skin of a subject, hereinafter “the second medical use of the invention”.

[0096] The terms "extract obtained from Ganoderma lucidum", "extract obtained from Hericium erinaceus", and "subject" have been explained above, and both they and their preferred embodiments are applicable to the present aspect of the invention. In the present invention, the term "treatment" refers to combating the effects caused as a consequence of a disease or pathological condition of interest in a subject (preferably a mammal, and more preferably a human), including:

[0097] (i) inhibit the disease or pathological condition, that is, stop its development;

[0098] (i) alleviate the disease or pathological condition, that is, cause the regression of the disease or pathological condition or its symptomatology;

[0099] (iii) stabilize the disease or pathological condition.

[0100] In the present invention, the term “prevention” refers to avoiding the occurrence of the disease, that is, preventing the disease or pathological condition from occurring in a subject (preferably a mammal, and more preferably a human), in particular, when said subject has a predisposition for the pathological condition.

[0101] The terms “side effect” or “adverse drug reaction,” as used interchangeably herein, refer to any harmful and unintended response to a drug that occurs at doses typically administered to a subject (preferably a mammal, and more preferably a human) for the prophylaxis, diagnosis, or treatment of disease and / or symptoms. Specifically, side effects of radiation therapy and / or chemotherapy on the skin include, but are not limited to, fibrosis, inflammation, dermatitis, skin fragility, skin fold erosions, nail loss, or dry skin.

[0102] The term "radiotherapy" refers to a form of treatment based on the use of ionizing radiation. Ionizing radiation includes X-rays or radioactivity, which includes gamma rays and alpha particles.

[0103] The term “chemotherapy” refers to a form of treatment based on the administration of chemical substances for the treatment of a disease, particularly cancer. Examples of chemotherapeutic agents that can cause side effects on the skin of the subjects to whom they are administered include, but are not limited to, doxorubicin, cyclophosphamide, thiotepa, daunorubicin, doxorubicin, epirubicin, 5-fluorouracil, methotrexate, 6-mercaptopurine, docetaxel, paclitaxel, vinblastine, vincrastine, vinchstine, actinomycin, bleomycin, mitomycin, etoposide or teniposide. In a preferred embodiment of the second medical use of the invention, the side effect of radiotherapy and / or chemotherapy is selected from the list consisting of: fibrosis, inflammation, dermatitis, skin fragility, erosions in skin folds, nail loss and / or dry skin.Preferably the side effect of radiotherapy and / or chemotherapy is selected from the list consisting of skin fragility, dermatitis and / or erosions in skin folds.

[0104] In a preferred embodiment of the second medical use of the invention, the combination of extracts comprises an extract obtained from the carpophore of Ganoderma lucidum and an extract obtained from the carpophore of Hericium erinaceus.

[0105] In another preferred embodiment of the second medical use of the invention, the extracts of the combination of the invention are administered to the subject simultaneously, separately or sequentially.

[0106] In a preferred embodiment of the second medical use of the invention, the route of administration is topical.

[0107] In another preferred embodiment of the second medical use of the invention, both the extract obtained from Ganoderma lucidum and the extract obtained from Hericium erinaceus are administered to the subject in a therapeutically effective dose, which can vary within a wide range. In the present invention, the expressions “therapeutically effective dose” or “therapeutically effective amount”, used interchangeably herein, refer to that quantity or dose of the extracts obtained from Ganoderma lucidum and Hericium erinaceus that when administered to a subject, preferably a mammal, and more preferably a human, is sufficient to produce the prevention and / or treatment of the side effects associated with radiotherapy and / or chemotherapy of the skin.The therapeutically effective amount will vary, for example, depending on the metabolic stability and duration of action of the extracts; the age, body weight, general health, sex, and diet of the subject; the mode and time of administration; the rate of excretion; the combination with other drugs; and the severity of the particular disease or pathological condition of said subject. It is routine practice for one skilled in the art, for example, a medical specialist, to determine the therapeutically effective dose for each subject, preferably a human, based on his or her own knowledge and the subject's physiological conditions or variables.

[0108] Since the extracts of the combination of the invention can be administered simultaneously, separately or sequentially, in a preferred embodiment the extracts of the combination of the invention are included in the same composition or in different compositions (that is, each of the extracts is found in a different composition). Both in different compositions and in the same composition, the Ganoderma lucidum extract is found in an amount between 0.005% m / m and 25% m / m, and where the Hericium erinaceus extract is found in an amount between 0.005% m / m and 25% m / m, either in different compositions or in the same one, where the % refers to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

[0109] In another even more preferred embodiment of the second medical use of the invention, both in different compositions and in the same composition, the Ganoderma lucidum extract is present in an amount between 0.25% m / m and 3% m / m, preferably in a concentration of 0.5% m / m, 1% m / m, 1.5% m / m, 2% m / m or 2.5% m / m, more preferably 0.5% m / m, and where the Hericium erinaceus extract is present in an amount between 0.25 m / m % and 3% m / m, preferably in a concentration of 0.5% m / m, 1% m / m, 1.5% m / m, 2% m / m or 2.5% m / m, more preferably 0.5% m / m, where the % refer to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

[0110] In a preferred embodiment of the second medical use of the invention, the composition or compositions comprising the extracts obtained from Ganoderma lucidum and Hericium erinaceus are pharmaceutical. In another preferred embodiment of the second medical use of the invention, said pharmaceutical composition or compositions also comprise a pharmaceutically acceptable carrier and / or excipient.

[0111] Thus, in another preferred embodiment of the second medical use of the invention, the pharmaceutically acceptable carrier and / or excipient is lactic acid, sodium hyaluronate, citric acid, sorbic acid, sodium benzoate, chitosan, water, and / or combinations thereof. The composition or compositions of the second medical use of the invention may be formulated for pharmaceutical administration. Thus, in a preferred embodiment of the second medical use of the invention, the composition or compositions are in liquid or semi-solid form, preferably formulated as a gel, cream, or ointment.

[0112] The combination of extracts of the invention can be applied to the area affected by the side effects of radiotherapy and / or chemotherapy, for example, the subject's skin. Therefore, the combination of extracts of the invention can be administered preventively to the area at risk of being affected by the side effects of radiotherapy and / or chemotherapy. The combination can be applied to said area, for example, comprised in the composition of the invention, by gently rubbing it in for a few minutes so that the skin can absorb the active ingredient. For example, but not limited to, the composition of the invention can be applied to the skin affected or at risk of being affected by the side effects of radiotherapy and / or chemotherapy, before or after radiotherapy and / or chemotherapy treatment.

[0113] Thus, in a preferred embodiment of the second medical use of the invention, the combination of the invention is administered to the subject before or after radiotherapy and / or chemotherapy treatment.

[0114] In another preferred embodiment of the second medical use of the invention, the composition comprising the extracts obtained from Ganoderma lucidum and Hericium erinaceus is the composition of the invention.

[0115] Chemotherapy or radiotherapy are two of the main treatment strategies for subjects suffering from cancer. Thus, in a preferred embodiment of the second medical use of the invention, the subject suffers from or is at risk of developing cancer.

[0116] The term "cancer" refers to a disease or group of diseases characterized by uncontrolled growth of an individual's cells. Depending on the tissue where the uncontrolled growth originates, examples of cancer include, but are not limited to, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, lymphoid cancer, or brain cancer.Thus, in a preferred embodiment of the second medical use of the invention, the cancer is selected from a group comprising: breast cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, lymphoid cancer, brain cancer, head and neck cancer, leukemia, lung cancer, colorectal cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer, stomach cancer, intestinal cancer, kidney cancer, multiple myeloma, non-small cell lung cancer, pancreatic cancer, glioblastoma, melanoma, colon cancer, lymphomas and / or neuroendocrine tumors. More preferably, the cancer or tumor is breast cancer.

[0117] In a preferred embodiment of the second medical use of the invention, the subject is a human or a non-human mammal.

[0118] In another aspect, the present invention relates to the non-therapeutic cosmetic use of a combination comprising an extract obtained from Ganoderma lucidum and an extract obtained from Heñcium eñnaceus, wherein said combination is administered topically to a subject, hereinafter "cosmetic use of the invention." The cosmetic use relates to preserving the integrity and / or improving the appearance of the skin, hair and / or mucous membranes of said subject.

[0119] The terms “extract obtained from Ganoderma lucidum”, “extract obtained from Heñcium eñnaceus” and “subject” have been explained above, and both they and their preferred embodiments are applicable to the present aspect of the invention.

[0120] In a preferred embodiment of the cosmetic use of the invention, the combination of extracts comprises an extract obtained from the carpophore of Ganoderma lucidum and an extract obtained from the carpophore of Heñcium eñnaceus.

[0121] In a preferred embodiment of the cosmetic use of the invention, the extracts of Ganoderma lucidum and Heñcium eñnaceus are administered to the subject simultaneously, separately or sequentially.

[0122] In another preferred embodiment of the cosmetic use of the invention, both the extract obtained from Ganoderma lucidum and the extract obtained from Hericium erinaceus are administered to the subject in a cosmetically effective dose, which may vary within a wide range. In the present invention, the expressions “cosmetically effective dose” or “cosmetically effective amount”, used interchangeably herein, refer to that quantity or dose of the extracts obtained from Ganoderma lucidum and Hericium erinaceus that when administered to a subject, preferably a mammal, and more preferably a human, is sufficient to preserve the integrity and / or improve the appearance of the skin, hair and / or mucous membranes of said subject.

[0123] In a preferred embodiment of the cosmetic use of the invention, the extracts of Ganoderma lucidum and Hericium erinaceus are included in the same composition or in different compositions (i.e., each of the extracts is found in a different composition).

[0124] Thus, in another preferred embodiment of the cosmetic use of the invention, both in different compositions and in the same composition, the Ganoderma lucidum extract is found in an amount of between 0.005% m / m and 25% m / m, and where the Hericium erinaceus extract is found in an amount of between 0.005% m / m and 25% m / m, either in different compositions or in the same one, where the % refer to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

[0125] In another even more preferred embodiment of the cosmetic use of the invention, both in different compositions and in the same composition, the Ganoderma lucidum extract is present in an amount between 0.25% m / m and 3% m / m, preferably in a concentration of 0.5% m / m, 1% m / m, 1.5% m / m, 2% m / m or 2.5% m / m, more preferably 0.5% m / m, and where the Hericium erinaceus extract is present in an amount between 0.25 m / m % and 3% m / m, preferably in a concentration of 0.5% m / m, 1% m / m, 1.5% m / m, 2% m / m or 2.5% m / m, more preferably 0.5% m / m, where the % refer to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

[0126] In a preferred embodiment of the cosmetic use of the invention, the composition or compositions comprising the extracts obtained from Ganoderma lucidum and Hericium erinaceus are cosmetic compositions, in which said cosmetic composition or compositions further comprise a cosmetically acceptable vehicle and / or excipient.

[0127] In another preferred embodiment of the cosmetic use of the invention, the composition or compositions are in liquid or semi-solid form.

[0128] In another preferred embodiment of the cosmetic use of the invention, the composition or compositions are formulated in the form of a gel, cream, or ointment.

[0129] In another preferred embodiment of the cosmetic use of the invention, the extracts obtained from Ganoderma lucidum and Hericium erinaceus are included in a cosmetic composition, preferably the composition of the invention.

[0130] In another preferred embodiment of the cosmetic use of the invention, the subject is a human or a non-human mammal.

[0131] In preferred embodiments of the composition of the invention, the first medical use of the invention, the second medical use of the invention or the cosmetic use of the invention, the extracts of Ganoderma lucidum and Hericium erinaceus are obtained by the method of obtaining the invention.

[0132] In preferred embodiments of the first medical use of the invention, the second medical use of the invention or the cosmetic use of the invention, the Ganoderma lucidum extract comprises the composition of p-glucans, ergosterol and ganoderic acid according to any one of the preferred embodiments of the composition of the invention; and the Hericium erinaceus extract comprises the composition of p-glucans, y-aminobutyric acid, ergosterol and hericenone c according to any one of the preferred embodiments of the composition of the invention.

[0133] EXAMPLES

[0134] The invention will then be illustrated by tests carried out by the inventors, which demonstrate the effectiveness of the product of the invention.

[0135] Example 1. Obtaining extracts of Hericium erinaceus and Ganoderma lucidum.

[0136] Process for obtaining the extract of Hericium erinaceus carpophore.

[0137] The method for preparing a fungal extract of Hericium erinaceus from carpophore cut to a size less than 1 cm comprises: a) extracting a fungal material by percolation using water and 50% ethanol as solvent with a solid-liquid ratio of 1:20, for 45 minutes at a temperature of 50 e C. After extraction, the mixture of solvent and extracted compounds that forms after the solvent comes into contact with the fungal material is separated by solid-liquid filtration. b) Dry the extract by spray drying. During spray drying, moisture evaporation occurs at a temperature between 135°F and 140°F. e C and 195 e C. During spray drying, maltodextrin is added as an encapsulating agent at a ratio of 4:14 extract:encapsulating agent.

[0138] The obtained extract of Hericium erinaceus carpophore contains 244 mg / g of beta-glucans, 51.2 pg / g of y-aminobutyric acid (GABA), 348.2 pg / g of ergosterol and 0.2 pg / g of Heñcenone C.

[0139] The quantification of p-glucans, y-aminobutyric acid, ergosterol, and hencenone c was performed following standardized methodologies. p-glucans were quantified using the p-glucan Enzyme Kit (Megazyme). y-Aminobutyric acid was quantified by HPLC following the methodology described by Gong et al. J. Inst. Brew.2017; 123: 417-422; ergosterol was quantified by HPLC-MS following the methodology described by Montgomery et al. Soil Biology and Biochemistry. 2020; 32: 1207-1217, and hencenone c was quantified by HPLC following the methodology described by Lee et al. Journal of Ethnopharmacology. 2016; 184: 219-225.

[0140] Process for obtaining the extract of Ganoderma lucidum carpophore.

[0141] The method for preparing a fungal extract of Ganoderma lucidum from carpophore cut to a size less than 1 cm comprises: a) extracting a fungal material by percolation using as solvent water and 50% ethanol with a solid liquid ratio of 1:20, for 45 minutes at a temperature of 50 e C. After extraction, the mixture of solvent and extracted compounds that forms after the solvent comes into contact with the fungal material is separated by solid-liquid filtration. b) Dry the extract by spray drying. During spray drying, moisture evaporation occurs at a temperature between 135°F and 140°F. e C and 195 e C. During spray drying, maltodextrin is added as an encapsulating agent at a ratio of 4:14 extract:encapsulating agent.

[0142] The obtained Ganoderma lucidum carpophore extract contains 582.8 mg / g of beta-glucans, 418 pg / g of ergosterol and 4.81 pg / g of ganoderic acid.

[0143] Quantification of p-glucans, ergosterol, and ganoderic acid was performed following standardized methodologies. p-glucans were quantified using the p-glucan Enzyme Kit (Megazyme). Ergosterol was quantified by high-performance liquid chromatography coupled to mass spectrometry (HPLC-MS) following the methodology described by Montgomery et al. Soil Biology and Biochemistry. 2020; 32: 1207–1217, and ganoderic acid was quantified by HPLC-MS following the methodology described by Qui et al. Front Farmacol. 2012; 3: 85.

[0144] Example 2. Isolation of primary fibroblasts, cell culture and treatments.

[0145] Primary cells isolated from patients were used in this study. Cell culture was performed in 10-centimeter (cm) diameter Petri dishes in Dulbecco's Modified Eagle Medium (DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin (P / S). Cells were incubated in culture incubators at 37°C. eC and 5% CO2. Dermal fibroblasts were cultured for 24h. Subsequently, Ganoderma lucidum carpophore extract was added at a concentration of 10 ng / mL, Hehcium ehnaceus carpophore extract at a concentration of 10 ng / mL and a mixture of Ganoderma lucidum carpophore extract and Hehcium ehnaceus carpophore extract at a concentration of 10 ng / mL, the mixture of Ganoderma lucidum carpophore extract and Hericium erinaceus carpophore extract is in a 1:1 ratio. The extracts were diluted in water to the mentioned concentrations. Fibroblasts to which no compound was added were used as a control. After 24 hours, samples were collected and mRNA expression levels of the cytokines IL-1β, IL-6, and IL-8 were analyzed using standardized methodologies. RNA extraction was performed using Tryzol® Reagent (Invitrogen) following the protocol described in the instruction manual.1 mL of Tryzol was added for cell lysis, allowing the sample to stand for 5 minutes at 4°C. Subsequently, 200 pL of chloroform was added, and centrifugation was carried out for 15 minutes at 12,000 rpm and 4. e C. The supernatant was selected and diluted in 500pL of isopropanol, homogenizing the preparation and centrifuged at 12,000 rpm for 15 min and 4 e C. Finally, 1 mL of cold 70% ethanol was added and the samples were centrifuged at 12,000 rpm for 5 minutes and 4 eC. RNA concentration was quantified using spectrophotometric techniques (Nanodrop ND-1000). Complementary DNA (cDNA) synthesis was then carried out from 1 mg of RNA using the Superscript® VILO™ cDNA Synthesis kit (Invitrogen). For gene expression analysis, real-time quantitative PCR (RT-qPCR) was performed. Each reaction used 5 pL of the cDNA dilution; 5 pL of primer mix in a 1:1 ratio (10 pM sense primer, 10 pM antisense primer); 10 pL of SYBR Green (PowerUPTM SYBRTM Green Master Mix, Thermo Fisher) in a real-time thermocycler (LightCyclerá480 System, Roche). The assays were performed in triplicate.

[0146] Ganoderma lucidum carpophore extract at a concentration of 10 ng / mL increased IL-6 mRNA expression and decreased IL-1 and IL-8 expression compared to untreated fibroblasts. Ganoderma lucidum carpophore extract had a pro-inflammatory effect against IL-6 (Table 1 ).

[0147] Hericium erinaceus carpophore extract at a concentration of 10 ng / mL decreased the expression of IL-1 and IL-8 compared to untreated fibroblasts. Hericium erinaceus carpophore extract had a proinflammatory effect against IL-1 and IL-6 (Table 1 ).

[0148] Table 1. IL-1p, IL-6 and IL-8 mRNA expression in untreated fibroblasts (UT), fibroblasts treated with Ganoderma lucidum carpophore extract at a concentration of 10 ng / mL (F2), fibroblasts treated with Hericium erinaceus extract at a concentration of 10 ng / mL (F3), fibroblasts treated with a mixture of Ganoderma lucidum carpophore extract and Hericium erinaceus carpophore extract (F5) at a concentration of 10 ng / mL.

[0149] Surprisingly, the combination of Ganoderma lucidum leaf extract with Hericium erinaceus leaf extract at a concentration of 10 ng / mL decreased the expression of various inflammatory cytokines compared to either extract alone. Specifically, we observed that for IL-6 and IL-8, the combination of Ganoderma lucidum leaf extract and Hericium erinaceus leaf extract reduced the expression of these cytokines by 25% and 23.65%, respectively, compared to the use of either extract alone. In fact, the combination of Ganoderma lucidum leaf extract and Hericium erinaceus leaf extract protected against the inflammatory effects induced by the use of either extract alone in the case of IL-6.

[0150] Administration of Ganoderma lucidum leaf extract combined with Hericium erinaceus leaf extract significantly reduced mRNA expression of the cytokines IL-1β, IL-6, and IL-8, especially IL-8, compared with administration of the fungal extracts alone. This combination is not expected to enhance the anti-inflammatory effect of the extracts.

[0151] Cytokines are important signaling molecules that mediate communicative interactions both locally between different cell types within dermal tissues and remotely between organs. Scientific studies indicate that the major cytokines in the skin cell response to ionizing radiation include IL-1 (interleukin-6), IL-6, and the chemokines IL-8.

[0152] Several studies correlate the expression of cytokine genes in skin tissues with acute and chronic skin toxicity induced by radiation and chemotherapy (Müller and Meineke. Exp HematoL 2007; 35(4 Suppl 1 ) :96- 104). In fact, the mechanism by which both treatments act is based on the induction of generalized senescence in tumor cells, which contributes to persistent local and systemic inflammation in the tissue. Senescent cells secrete a series of inflammatory factors into the extracellular medium called senescence-associated secretory phenotype (SASP). The secretion of SASP is beneficial in the short term since it allows the activation of the immune system and consequently favors the elimination of senescent cells from the tissue.However, long-term SASP generates an environment of prolonged and sustained inflammation that hinders the elimination of tumor cells, even promoting their proliferative capacity.

[0153] Therefore, inflammation is an inherent component of the chronic effects induced by radiation and chemotherapy, suggesting that inhibition of inflammation, including suppression of the acute effects of inflammatory cytokine gene expression, would reduce skin toxicity, thus a composition or combination comprising the extracts of Ganoderma lucidum and Hericium erinaceus can be used in the prevention and / or treatment of side effects associated with radiotherapy and / or chemotherapy (Wyld et al. Cancers. 2020. 12(8): 2134; Krtolica et al. Biological Science. 2001. 98 (21 ) 12072-12077).

Claims

CLAIMS 1. A topical composition comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus.

2. Composition according to claim 1, wherein the extract obtained from Ganoderma lucidum is an extract obtained from the carpophore of Ganoderma lucidum; and wherein the extract from Hericium erinaceus is an extract obtained from the carpophore of Hericium erinaceus.

3. Composition according to any one of claims 1 or 2, wherein the G. lucidum extract comprises p-glucans, ergosterol, and ganoderic acid; and wherein the H. erinaceus extract comprises p-glucans, y-aminobutyric acid, ergosterol, and hericenone c.

4. Composition according to any one of claims 1 to 3, wherein the G. lucidum extract comprises: Between 524 mg / g and 641 mg / g of p-glucans; Between 376 pg / g and 460 pg / g of ergosterol; and Between 4.30 pg / g and 5.30 pg / g of ganoderic acid.

5. Composition according to any one of claims 1 to 4, wherein the H. erinaceus extract comprises: Between 220 mg / g and 268 mg / g of p-glucans; Between 46 pg / g and 56.32 pg / g of y-aminobutyric acid; Between 313.39 pg / g and 382.80 pg / g of ergosterol; and Between 0.18 pg / g and 0.22 pg / g of hericenone c.

6. Composition according to any one of claims 1 to 5, characterized in that: -G. lucidum extract is found in an amount between 0.005% and 25%, and - H. erinaceus extract is found in an amount between 0.005% and where the % refer to the % m / m of each of the extracts with respect to the total composition.

7. Composition according to any one of claims 1 to 6, wherein said composition is in liquid or semi-solid form.

8. Composition according to any one of claims 1 to 7, wherein the composition is in the form of a gel, cream or ointment.

9. Composition according to any one of claims 1 to 8, wherein said composition is a pharmaceutical composition or a cosmetic composition.

10. Composition according to claim 9, wherein said composition further comprises a pharmaceutically or cosmetically acceptable carrier and / or excipient.

11. Combination comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus for use as a medicament where said medicament is administered topically.

12. Combination comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus, for use in the treatment and / or prevention of the side effects of radiotherapy and / or chemotherapy on the skin of a subject, where said combination is administered topically.

13. Combination for use according to either of claims 11 or 12, wherein the extract obtained from Ganoderma lucidum is an extract obtained from the carpophore of Ganoderma lucidum; and wherein the extract from Hericium erinaceus is an extract obtained from the carpophore of Hericium erinaceus.

14. Combination for use according to any one of claims 12 or 13 wherein the side effect of radiotherapy and / or chemotherapy is selected from the list consisting of: fibrosis, inflammation, dermatitis, skin fragility, erosions in skin folds, nail loss and / or dry skin.

15. Combination for use according to any one of claims 1 to 14, wherein the Ganoderma lucidum extract and the Hericium erinaceus extract are administered simultaneously, separately or sequentially.

16. Combination for use according to any one of claims 1 to 15, wherein the extracts of Ganoderma lucidum and Hericium erinaceus are included in the same composition or in different compositions, preferably where the extract of Ganoderma lucidum is present in an amount between 0.005% m / m and 25% m / m, and where the extract of Hericium erinaceus is present in an amount between 0.005% m / m and 25% m / m, where the % refer to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

17. Combination for use according to claim 16, wherein the composition or compositions are pharmaceutical.

18. Combination for use according to claim 17, wherein said composition or compositions further comprise a pharmaceutically acceptable carrier and / or excipient.

19. Combination for use according to any one of claims 16 to 18, wherein said composition or compositions are in liquid or semi-solid form.

20. Combination for use according to any one of claims 16 to 19, wherein the composition or compositions are formulated in the form of a gel, cream or ointment.

21. Combination for use according to any one of claims 16 to 20, wherein the composition comprising the extract obtained from Ganoderma lucidum and the extract obtained from Hericium erinaceus, is the composition according to any one of claims 1 to 10.

22. Combination for use according to any one of claims 12 to 21, wherein the subject suffers from cancer, preferably breast cancer.

23. Combination for use according to any one of claims 12 to 22, wherein the subject is a human or a non-human mammal.

24. Non-therapeutic cosmetic use of a combination comprising an extract obtained from Ganoderma lucidum and an extract obtained from Hericium erinaceus, where said combination is administered topically to a subject.

25. Non-therapeutic cosmetic use according to claim 24, wherein the extract obtained from Ganoderma lucidum is an extract obtained from the carpophore of Ganoderma lucidum; and wherein the extract from Hericium erinaceus is an extract obtained from the carpophore of Hericium erinaceus.

26. Non-therapeutic cosmetic use according to any one of claims 24 or 25, wherein the Ganoderma lucidum extract and the Hericium erinaceus extract are administered simultaneously, separately or sequentially.

27. Non-therapeutic cosmetic use according to any one of claims 24 to 26, wherein the extracts of Ganoderma lucidum and Hericium erinaceus are included in the same composition or in different compositions, preferably where the extract of Ganoderma lucidum is present in an amount between 0.005% m / m and 25% m / m, and where the extract of Hericium erinaceus is present in an amount between 0.005% m / m and 25% m / m, where the % refers to the % m / m of each of the extracts with respect to the total of the composition in which they are found.

28. Non-therapeutic cosmetic use according to claim 27, wherein the composition or compositions are cosmetic.

29. Non-therapeutic cosmetic use according to claim 28, wherein said composition or compositions further comprise a cosmetically acceptable vehicle and / or excipient.

30. Non-therapeutic cosmetic use according to any one of claims 27 to 29, wherein said composition or compositions are in liquid or semi-solid form.

31. Non-therapeutic cosmetic use according to any one of claims 27 to 30, wherein the composition or compositions are formulated in the form of a gel, cream or ointment.

32. Non-therapeutic cosmetic use according to any one of claims 27 to 31, wherein the composition comprising the extract obtained from Ganoderma lucidum and the extract obtained from Hericium erinaceus, is the composition according to any one of claims 1 to 10.

33. Non-therapeutic cosmetic use according to any one of claims 24 to 32, wherein the subject is a human or a non-human mammal.

Citation Information

Patent Citations

  • BB cream containing hericium erinaceus extract

    CN105816394A

  • American ginseng root lucid ganoderma mushroom powder

    CN108042588A

  • Exosome composite preparation for skin light injury repair and preparation method thereof

    CN114344360A

  • Heat-loss managing system for vehicle and controlling method therefor

    KR102687174B1

  • Fungus polysaccharide and preparation process thereof

    CN104351613A